What’s New in Caring for People Living with HIV Infection? An Update for the Pharmacist
This on-demand module will provide pharmacists with updated information on treatment options for people living with HIV. Content includes introductions to new treatment types, regimens, and overview clinical trial data. Following this activity, participants should be able to assist with infection management and incorporate the information into patient counseling.
Upon completion of this activity, the participant will be able to:
- Discuss selection of initial antiretroviral therapy for an individual patient, including dosing, adverse effects, food requirements, and patient counseling points.
- Identify the role of recently approved agents in the treatment of HIV infection, including long acting cabotegravir plus rilpivirine.
- Plan how to incorporate counseling for people living with HIV infection into a variety of pharmacy practice settings.
Linda Spooner, PharmD, BCPS, FASHP, FCCP | Professor of Pharmacy Practice
Massachusetts School of Pharmacy and Health Science
Registration Fee: Free for MCPHS alumni and full-time employees; $12.00 for all other professionals.
Release Date: March 10, 2022
Expiration Date: March 24, 2023
ACPE UAN: 0026-0000-22-103-H02-P | Knowledge
ACPE Topic Designator: AIDS Therapy
Contact Hours: 1 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.0 contact hours (0.1 CEUs).
To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Linda Spooner has attended a one day advisory board meeting for TheraTechnologies. Conflicts have been mitigated through a peer review process per MCPHS Policy.
Off-label/investigational uses of a lenacapavir will be discussed. This agent is on a clinical hold at this time (1/2022).
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.